Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in
Advertisement

Pulmonx Corporation LUNG

Set alert

Price alert · LUNG

All alert types
3.01 USD -0.16 -5.06%

At close · Oct 30

2.98 -0.02 -0.83%

After hours · Oct 30, 7:48 PM ET

Bid
3.00 × 2
Ask
3.01 × 3
2.79 Day range 3.23
1.17 52-week range 3.16
YTD
+35.97%
1 year
+70.74%
Open
3.07
Prev close
3.17
Mkt cap
126.92M
Vol
2.41M
Avg vol
618.68K
EPS
-1.01
P/E
0.00
Div yield
0.00%
More statistics
Low
2.79
High
3.23
Forward P/E
-3.91
Beta
0.68
Short ratio
3.62
Inst. own
94.86%
Dividend
0.00
Ex-div date
Earnings
Jul 31, 2024
50-d avg
6.51
200-d avg
7.33
1y target
11.92

3M chart

Chart tools
Interval
1m5m15m30m

Signals (15)
NameDateAgo
SMA: BullishOct 28, 20264 days ago
RSI: OverboughtOct 28, 20264 days ago
SMA: BullishOct 26, 20266 days ago
MACD: Buy SignalOct 20, 20261 week ago
SMA: BearishSep 24, 20261 month ago
SMA: BullishSep 14, 20261 month ago
SMA: BearishSep 10, 20261 month ago
SMA: BearishSep 8, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
MACD: Buy SignalAug 25, 20262 months ago
RSI: OverboughtAug 25, 20262 months ago
MACD: Sell SignalAug 24, 20262 months ago
RSI: OverboughtAug 14, 20262 months ago
RSI: OverboughtAug 6, 20262 months ago
RSI: OverboughtAug 3, 20263 months ago

Key statistics

Financials
Market cap
247.19M
Enterprise value
190.88M
Trailing P/E
0.00
Forward P/E
-3.91
PEG ratio
0.00
Price / sales
3.12
Price / book
2.63
EPS (TTM)
-1.47
Beta
0.68
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-72.01%
Revenue (TTM)
79.30M
Revenue growth
15.40%
Free cash flow
-14.47M
Total cash
107.78M
Total debt
55.81M
Return on equity
-51.99%
Shares outstanding
39.49M
Short % of float
2.92%
50-day average
6.51
200-day average
7.33

Analyst view

Consensus: buy

Buy
Price target (mean) 11.92 +296.6% upside
Target (low)
7.50
Target (mean)
11.92
Target (high)
16.00
Ratings (0m) 6 4 buy · 2 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Jul 31, 2024

Expected Jul 31, 2024. Consensus EPS estimate -0.44894.

Earnings history

Financials — quick view

All financials
LUNG Revenue — quarterly 22.76M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LUNG Net income — quarterly -10.08M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LUNG EPS — quarterly -0.24
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

LUNG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 30, 2024Sep 1, 2024-0.43-0.36+0.07+16.28%
Jul 31, 2024Jun 1, 2024-0.41-0.39+0.02+4.88%
Jul 31, 2024Jun 1, 2024-0.41———
May 1, 2024Mar 1, 2024-0.43-0.36+0.07+16.28%
May 1, 2024Mar 1, 2024-0.43———
Feb 21, 2024Dec 1, 2023-0.39———

Upgrades / downgrades

LUNG analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024Wells FargomainEqual-WeightEqual-Weight
Dec 11, 2024CitigroupdownBuyNeutral
Oct 31, 2024StifelmainBuyBuy
Aug 1, 2024Piper SandlermainOverweightOverweight
Aug 1, 2024Canaccord GenuitymainBuyBuy
Aug 1, 2024Wells FargomainEqual-WeightEqual-Weight

About Pulmonx Corporation

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
pulmonx.com

News

All news

Your note

Sign in to keep a note on LUNG — it syncs with the Stock Master app.

Insider holders

LUNG insider holders
InsiderRelationLatest transactionDateShares held
BURNS THOMAS WILLIAMDirectorStock Award(Grant)Jun 2, 202436,246
FERRARI RICHARD MDirectorStock Award(Grant)Jun 2, 202457,871
FLORIN DANIEL PDirectorStock Award(Grant)Jun 2, 202456,757
FRENCH GLENDON E IIIDirectorSaleNov 21, 20241,071,970
LEHMAN DAVID AARONGeneral CounselSaleDec 1, 2024197,851
MEAD DANA G JRDirectorStock Award(Grant)Jun 2, 202466,637

Institution ownership

LUNG institution ownership
Holder% heldSharesValueReported
FMR, LLC14.87%5,872,88236.76MSep 29, 2024
Primecap Management Company14.37%5,676,01135.53MSep 29, 2024
Morgan Stanley9.60%3,788,94523.72MSep 29, 2024
Blackrock Inc.7.08%2,795,56117.50MSep 29, 2024
Vanguard Group Inc5.77%2,278,90514.27MSep 29, 2024
Deutsche Bank Aktiengesellschaft2.84%1,121,8407.02MSep 29, 2024

Fund ownership

LUNG fund ownership
Holder% heldSharesValueReported
Primecap Odyssey Aggressive Growth Fund9.78%3,861,21624.17MSep 29, 2024
Fidelity Small Cap Growth Fund3.78%1,493,4729.35MAug 30, 2024
Fidelity Select Portfolios - Pharmaceuticals3.63%1,431,5228.96MOct 30, 2024
Vanguard Total Stock Market Index Fund2.94%1,161,6717.27MSep 29, 2024
iShares Russell 2000 ETF2.48%978,9306.13MOct 30, 2024
Fidelity Advisor Small Cap Fund2.11%832,4005.21MAug 30, 2024
Advertisement